Healwell AI Inc. Share Price Börse Stuttgart

Equities

6H90

CA42249X1006

Healthcare Facilities & Services

Real-time Estimate Tradegate 19:54:02 17/06/2024 BST 5-day change 1st Jan Change
1.86 EUR +3.33% Intraday chart for Healwell AI Inc. +19.21% +267.35%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 41.21M 30.03M 27.98M 2.36B Sales 2025 * 72.44M 52.78M 49.18M 4.15B Capitalization 373M 272M 253M 21.38B
Net income 2024 * -22M -16.03M -14.94M -1.26B Net income 2025 * -17M -12.39M -11.54M -975M EV / Sales 2024 * 9.05 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 5.15 x
P/E ratio 2024 *
-15.4 x
P/E ratio 2025 *
-30.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 44.66%
More Fundamentals * Assessed data
Dynamic Chart
Healwell AI Agrees to Buy BioPharma Services For $11.9 Million to Expand Clinical Research Offerings MT
Healwell AI Inc. agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million. CI
Healwell AI Agrees to Buy VeroSource Solutions for $24.5 Million to Add its Cloud-Based Health Data Interoperability Platform MT
Healwell AI Inc. agreed to acquire VeroSource Solutions Inc. for CAD 24.5 million on June 11, 2024. CI
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema MT
HEALWELL AI Unit Partners With Takeda for Rare Disease Evidence Analysis MT
HEALWELL AI Brief: Subsidiary Pentavere Announcing Partnership with Takeda to "Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema" MT
HEALWELL AI Appoints Anthony Lam as its Chief Financial Officer MT
HEALWELL AI Brief: Lam will replace Scott Nirenberski who has been CFO since Sept 2020 MT
HEALWELL AI Brief: Appointing Anthony Lam as New Chief Financial Officer MT
Healwell AI Inc. Announces Chief Financial Officer Changes CI
Healwell AI Closes Upsized $20 Million Bought-Deal Private Placement of Share Units MT
Healwell AI Inc. announced that it has received CAD 20.00025 million in funding CI
Healwell AI Subsidiary Partners With Sunnybrook Hospital to Show AI Platform Role in Cancer Staging MT
Healwell AI Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
1 week+19.21%
Current month+45.16%
1 month+79.10%
3 months+162.77%
6 months+236.45%
Current year+267.35%
More quotes
1 week
1.57
Extreme 1.57
2.43
1 month
0.97
Extreme 0.974
2.43
More quotes
Managers TitleAgeSince
Founder - 31/08/20
Corporate Officer/Principal - 31/12/12
Corporate Officer/Principal - 01/10/23
Members of the board TitleAgeSince
Chairman 49 30/09/23
Director/Board Member 66 28/12/20
Director/Board Member 60 28/12/20
More insiders
Date Price Change
17/06/24 1.855 +3.06%
14/06/24 1.8 -2.70%
13/06/24 1.85 -7.96%
12/06/24 2.01 +7.49%
11/06/24 1.87 -4.10%

Delayed Quote Börse Stuttgart, June 17, 2024 at 06:14 pm

More quotes
HEALWELL AI Inc. is a healthcare technology company focused on artificial intelligence (AI) and data science for preventative care. The Company is engaged in developing and acquiring technology and clinical sciences capabilities. Its clinical information sources consist of clinician and electronic medical records (EMR) access; clinical research and trials; lab and diagnostic info, and semi-structured data. It offers a range of clinical insights with life sciences companies, precision medicine companies, pharmaceutical companies, and medical device companies. It also focuses on identifying eligible patients for approved medications and interventions through its AI system, DARWEN. It offers Intrahealth an advanced software-as-a-service based HER management platform for small and medium enterprise healthcare organizations across Canada, Australia, and New Zealand. The platform meets the demands of a clients from a single doctor’s office to a multi-thousand user health institution.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.84 CAD
Average target price
3.68 CAD
Spread / Average Target
+29.58%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW